Pfenex Inc (NYSEAMERICAN:PFNX) was the target of a significant growth in short interest in the month of December. As of December 29th, there was short interest totalling 198,379 shares, a growth of 13.4% from the December 15th total of 174,975 shares. Currently, 1.0% of the company’s shares are sold short. Based on an average daily volume of 721,971 shares, the short-interest ratio is currently 0.3 days.

A number of large investors have recently made changes to their positions in PFNX. Legal & General Group Plc boosted its holdings in Pfenex by 2,567.5% in the second quarter. Legal & General Group Plc now owns 110,249 shares of the biotechnology company’s stock worth $442,000 after acquiring an additional 106,116 shares in the last quarter. AJO LP bought a new position in Pfenex in the second quarter worth approximately $946,000. Dimensional Fund Advisors LP boosted its holdings in Pfenex by 112.1% in the second quarter. Dimensional Fund Advisors LP now owns 201,066 shares of the biotechnology company’s stock worth $806,000 after acquiring an additional 106,257 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Pfenex by 186.0% in the second quarter. Goldman Sachs Group Inc. now owns 160,204 shares of the biotechnology company’s stock worth $642,000 after acquiring an additional 104,184 shares in the last quarter. Finally, Susquehanna International Group LLP bought a new position in Pfenex in the second quarter worth approximately $272,000.

Pfenex (NYSEAMERICAN:PFNX) traded up $0.01 during midday trading on Wednesday, reaching $3.17. The company had a trading volume of 27,700 shares, compared to its average volume of 178,533. Pfenex has a fifty-two week low of $2.07 and a fifty-two week high of $9.67. The firm has a market capitalization of $79.59, a PE ratio of -1.78 and a beta of 3.95.

Pfenex (NYSEAMERICAN:PFNX) last released its earnings results on Thursday, November 9th. The biotechnology company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.17. Pfenex had a negative return on equity of 63.57% and a negative net margin of 175.52%. The business had revenue of $5.02 million during the quarter, compared to analysts’ expectations of $3.30 million. During the same quarter last year, the firm posted $1.46 earnings per share. The firm’s revenue was down 89.7% on a year-over-year basis.

Several equities research analysts recently commented on PFNX shares. Zacks Investment Research raised Pfenex from a “strong sell” rating to a “hold” rating in a research note on Wednesday, October 11th. JMP Securities decreased their target price on Pfenex from $21.00 to $8.00 and set an “outperform” rating for the company in a research note on Friday, November 10th. Two research analysts have rated the stock with a sell rating and one has issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $5.50.

COPYRIGHT VIOLATION NOTICE: “Short Interest in Pfenex Inc (PFNX) Increases By 13.4%” was posted by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.watchlistnews.com/short-interest-in-pfenex-inc-pfnx-increases-by-13-4/1801713.html.

About Pfenex

Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).

Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with Analyst Ratings Network's FREE daily email newsletter.